1 - 1 out of 1Page size: 10
  1. 2022

  2. Selective targeting BMP2 and 4 in SMAD4 negative esophageal adenocarcinoma inhibits tumor growth and aggressiveness in preclinical models

    Members of the Esophageal Adenocarcinoma Study Group Europe (EACSGE), Aug 2022, In: Cellular oncology. 45, 4, p. 639-658 20 p.

    Research output: Contribution to journal › Article › Academic › peer-review

ID: 82268